Methods of Inactivation of SARS-CoV-2 for Downstream Biological Assays.
SARS-Cov-2
Trizol
detergents
inactivation
methanol
paraformaldehyde
temperature
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
received:
12
06
2020
accepted:
06
08
2020
pubmed:
17
8
2020
medline:
21
10
2020
entrez:
17
8
2020
Statut:
ppublish
Résumé
The scientific community has responded to the coronavirus disease 2019 (COVID-19) pandemic by rapidly undertaking research to find effective strategies to reduce the burden of this disease. Encouragingly, researchers from a diverse array of fields are collectively working towards this goal. Research with infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is undertaken in high-containment laboratories; however, it is often desirable to work with samples at lower-containment levels. To facilitate the transfer of infectious samples from high-containment laboratories, we have tested methods commonly used to inactivate virus and prepare the sample for additional experiments. Incubation at 80°C, a range of detergents, Trizol reagents, and UV energies were successful at inactivating a high titer of SARS-CoV-2. Methanol and paraformaldehyde incubation of infected cells also inactivated the virus. These protocols can provide a framework for in-house inactivation of SARS-CoV-2 in other laboratories, ensuring the safe use of samples in lower-containment levels.
Identifiants
pubmed: 32798217
pii: 5892951
doi: 10.1093/infdis/jiaa507
pmc: PMC7529010
doi:
Substances chimiques
Detergents
0
Guanidines
0
Phenols
0
Polymers
0
trizol
0
Formaldehyde
1HG84L3525
paraform
Y19UC83H8E
Methanol
Y4S76JWI15
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1462-1467Subventions
Organisme : Department of Health
ID : IS-HPU-1112-10117
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V033441/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R21 AI138074
Pays : United States
Organisme : Medical Research Council
ID : MR/R015406/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R21 AI129507
Pays : United States
Organisme : Cancer Research UK
Pays : United Kingdom
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
J Histochem Cytochem. 1997 Mar;45(3):327-43
pubmed: 9071315
J Virol Methods. 2018 Apr;254:31-34
pubmed: 29407211
Med Microbiol Immunol. 2005 Jan;194(1-2):1-6
pubmed: 15118911
Vox Sang. 2004 May;86(4):230-8
pubmed: 15144527
J Virol Methods. 2004 Oct;121(1):85-91
pubmed: 15350737
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Clin Chem. 2020 Jun 1;66(6):794-801
pubmed: 32246822
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
J Photochem Photobiol B. 2001 Oct;63(1-3):88-102
pubmed: 11684456
Virol J. 2010 Feb 18;7:40
pubmed: 20167059
Viruses. 2020 Jun 08;12(6):
pubmed: 32521706
Biologicals. 2005 Jun;33(2):95-9
pubmed: 15939287
J Biol Chem. 2000 Sep 1;275(35):26732-42
pubmed: 10827179
J Clin Lab Anal. 2020 Sep;34(9):e23411
pubmed: 32594577
J Virol Methods. 2020 Feb;276:113794
pubmed: 31794780
Dermatology. 2006;212 Suppl 1:119-23
pubmed: 16490989